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The latent membrane protein 2A (LMP2A) of Epstein–Barr virus (EBV) is an important mediator of viral latency in infected B-
lymphocytes. LMP2A inhibits B-cell receptor (BCR) signaling in vitro and allows for the survival of BCR-negative B cells in vivo. In this
study, we compared gene transcription in BCR-activated B cells from non-transgenic and LMP2A Tg6 transgenic mice. We found that the
transcriptional induction and down-regulation of many genes that normally occurs in B cells following BCR activation did not occur in B
cells from LMP2A Tg6 transgenic mice. Furthermore, LMP2A induced the expression of various transcription factors and genes associated
with DNA/RNA metabolism, which may allow for the altered transcriptional regulation observed in BCR-activated B cells from LMP2ATg6
mice. These results suggest that LMP2A may inhibit the downstream effects of BCR signaling by directly or indirectly altering gene
transcription to ensure EBV persistence in infected B cells.
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Epstein–Barr virus (EBV) infection is associated with
the development of a variety of malignancies of both
lymphoid and epithelial origin, including Hodgkin’s lym-
phoma, Burkitt’s lymphoma, nasopharyngeal carcinoma,
and various lymphoproliferative disorders arising in im-
munocompromised individuals (Kieff and Rickinson,
2001; Thorley-Lawson, 2001). Primary EBV infection
usually occurs during childhood and, following an initial,
self-limiting infection, EBV establishes a lifelong latent
infection in B lymphocytes. Viral gene expression in
latently infected B cells is limited to transcription of
EBV nuclear antigen 1 (EBNA1), latent membrane pro-
tein 2A (LMP2A), EBV-encoded RNAs (EBERs), and
BamHI-A-rightward transcripts (BARTS) (Chen et al.,
1995, 1999; Qu and Rowe, 1992; Thorley-Lawson,
2001; Tierney et al., 1994). The consistent detection of
LMP2A transcripts in both tumor cells and latently0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: r-longnecker@nwu.edu (R. Longnecker).infected B cells in vivo suggests that LMP2A plays an
important role in viral persistence and in the development
of EBV-associated diseases.
In latently infected lymphocytes, LMP2A resides in
small glycolipid-enriched microdomains in the plasma
membrane, where it appears to mimic an activated B-cell
receptor (BCR) (Dykstra et al., 2001; Longnecker, 2000).
BCR activation in LMP2A-expressing cells fails to induce
calcium mobilization and activation of the downstream
signaling molecules Lyn, Syk, phosphatidylinositol 3-
kinase (PI3-K), phospholipase C-g2 (PLCg2), Vav, Shc,
and mitogen-activated protein kinase (MAPK) (Miller et al.,
1995, 1993). Instead, these molecules are constitutively
phosphorylated in the presence of LMP2A. The amino-
terminal cytoplasmic domain of LMP2A contains eight
tyrosines (Burkhardt et al., 1992; Miller et al., 1995).
Phosphotyrosines at positions 74 and 85 (an immunore-
ceptor tyrosine-based motif (ITAM)) in LMP2A bind the
protein tyrosine kinase Syk while tyrosine 112 binds the
Src family kinase Lyn. Mutational analyses indicate that all
three residues are essential for the LMP2A-mediated block
in BCR signaling (Fruehling and Longnecker, 1997;
Fruehling et al., 1998). It is likely that LMP2A provides
a constitutive positive signal and, by sequestering Lyn and
Syk, prevents normal BCR signal transduction. By inhib-
Fig. 1. Increased tyrosine phosphorylation in purified B cells following
BCR activation. B cells from wild-type (WT) and LMP2A Tg6 transgenic
mice were treated with goat anti-mouse Ig for 5 min to activate the BCR.
Cell lysates were extracted from 5  106 cells and equivalent amounts of
protein were utilized for Western blot analysis with anti-phosphotyrosine
antibodies. Tyrosine phosphorylation was similarly induced in both wild-
type and LMP2A Tg6 B cells following BCR activation.
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of lytic EBV replication and subsequent immune recogni-
tion of infected cells.
Mice transgenic for LMP2A have demonstrated that
this protein is able to interfere with normal B-cell
development, allowing BCR-negative cells to exit the
bone marrow and colonize peripheral organs (Caldwell
et al., 1998). Two types of LMP2A transgenic lines have
been described. The TgE line has significantly reduced
numbers of CD19+ B cells in the bone marrow and
spleen and a significant percentage of these B cells do
not express surface immunoglobulin (Ig). Furthermore,
bone marrow B cells from these mice undergo Ig light
chain, but not heavy chain, gene rearrangement (Caldwell
et al., 1998, 2000). This indicates that LMP2A signaling
can bypass the requirement for Ig recombination and
allow BCR-negative cells, which would normally undergo
apoptosis, to colonize peripheral lymphoid organs. The
LMP2A-mediated effects on B-cell development and
survival in vivo have been shown to require the ITAM
(Syk binding) (Merchant et al., 2000). In addition, studies
utilizing mice deficient for the downstream B-cell signal-
ing components BLNK (SLP-65) or Bruton’s tyrosine
kinase (Btk) have demonstrated that LMP2A utilizes
these molecules for its effects on B-cell developmentFig. 2. Comparison of gene expression profiles in wild-type and LMP2A
Tg6 B cells. The average differences in hybridization intensities for genes
in each sample were plotted against each other in graphs to demonstrate
the overall similarities and differences in gene expression in unstimulated
and BCR-activated B cells from wild-type (WT) and LMP2A Tg6
transgenic mice. Plotted against each other are the average differences in
gene expression in (A) unstimulated (unst) and BCR-activated (+Ig) wild-
type B cells, (B) unstimulated and BCR-activated B cells from LMP2A
Tg6 transgenic mice, (C) BCR-activated B cells from wild-type and Tg6
transgenic mice, and (D) unstimulated B cells from wild-type and Tg6
transgenic mice.
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necker, 2001).
The LMP2A Tg6 transgenic line displays lower levels
of LMP2A mRNA expression and a more subtle pheno-
type in a wild-type background, demonstrating a slight
reduction in the total number of mature, BCR-positive B
cells. However, crosses between LMP2A Tg6 transgenic
mice and mice deficient for recombinase-activating gene-
1 (RAG-1) result in the production of BCR-negative cells
in peripheral lymphoid organs similar to TgE LMP2A
mice (Caldwell et al., 2000). This suggests that the extent
to which LMP2A can bypass normal B-cell developmen-
tal checkpoints correlates with the transgene expression
levels; however, the presence of BCR-positive cells in the
LMP2A Tg6 line provides a unique model in which to
specifically study the effects of LMP2A on BCR signal-
ing in vivo.
Through the use of DNA microarray technology, many
transcriptional abnormalities have been identified in B
cells from the LMP2A TgE transgenic line. In these cells,
LMP2A appears to globally repress the expression of
genes associated with normal B-cell development as well
as transcription factors that regulate expression of those
genes (Portis and Longnecker, 2003). In this study, weFig. 3. Differential changes in gene expression in BCR-activated B cells from w
increased or decreased upon BCR activation (+Ig) of B cells from wild-type (WT
expression values of twofold or greater and probability values of less than 0.05 w
protein function. The percentages of genes in each category relative to the overall ihave analyzed gene expression in splenic B cells from
the LMP2A Tg6 transgenic line following BCR activa-
tion. Our studies indicate that, compared to gene expres-
sion in activated B cells from non-transgenic mice,
LMP2A interferes with the transcriptional induction and
down-regulation of many genes that normally occurs
upon BCR activation.Results
BCR activation of B cells from wild-type and LMP2A Tg6
transgenic mice
To determine the effects of LMP2A on BCR signaling in
primary B cells, we utilized DNA microarray analysis to
directly compare gene transcription in unstimulated and
BCR-activated B cells from LMP2A Tg6 transgenic mice
and non-transgenic littermates. Activation of B cells was first
verified by measuring phosphotyrosine activity following
treatment of cells with anti-mouse Ig to stimulate BCR
signaling. Fig. 1 indicates that BCR activation of purified B
cells from both wild-type (WT) and LMP2A Tg6 mice
resulted in increased tyrosine phosphorylation (compareild-type versus LMP2A Tg6 transgenic mice. (A) The percentage of genes
) versus LMP2A Tg6 mice is indicated. Genes with changes in differential
ere included. (B) Genes were annotated and placed in categories based on
ncreases (bars 1 and 2) or decreases (bars 3 and 4) in expression are shown.
Table 1
Genes induced in BCR-activated B cells from wild-type mice or down-regulated in BCR-activated LMP2A Tg6 mice
Gene Name WT + Ig Tg6 + Ig Function
Changea Callb Change Call
p21 (CDKN1A)-activated kinase 3 Pak3 2.5 I 1.7 NC cell cycle/apoptosis
a disintegrin and metalloprotease domain 2 Adam2 2.3 I  0.4 NC cell–cell interactions
laminin, beta 2 Lamb2 2.2 I  0.4 NC cell–cell interactions
neural cell adhesion molecule 2 Ncam2 3.1 I 0.1 NC cell–cell interactions
Norrie disease homolog Ndph 2.8 I 0.4 NC cell–cell interactions
neuropilin Nrp 2.8 I  1.1 NC cell–cell interactions
S100 calcium binding protein A1 S100a1 2.3 MI 1.3 NC cell–cell interactions
aspartyl-tRNA synthetase Asprs 2.1 I 1 NC DNA/RNA metabolism
H1 histone family, member O (oocyte-specific) H1fo 2.8 I  0.7 NC DNA/RNA metabolism
nuclear distribution gene C homolog (Aspergillus) Nudc 2 MI 0.5 NC DNA/RNA metabolism
nuclear distribution gene E-like Nudel 2.7 I  0.7 NC DNA/RNA metabolism
transcription factor A, mitochondrial Tfam 2.3 I  0.7 NC DNA/RNA metabolism
cytochrome c oxidase, subunit VIIIb Cox8b 2.8 I 0.4 NC enzymes/metabolism
cytochrome P450, 17 Cyp17 2.6 I  1 NC enzymes/metabolism
kallikrein 6 Klk6 3.5 I  0.7 NC enzymes/metabolism
kallikrein B, plasma 1 Klkb1 2.9 I 0.7 NC enzymes/metabolism
procollagen-proline, 2-oxoglutarate 4-dioxygenase
(proline 4-hydroxylase)
P4ha2 2.8 I 1.1 NC enzymes/metabolism
phosphodiesterase 1A, calmodulin-dependent Pde1a 2.4 I 1.5 NC enzymes/metabolism
serine dehydratase related sequence 1 Sds-rs1 2.6 I 0 NC enzymes/metabolism
CD160 antigen Cd160 3.3 I 0.9 NC inflammation/immunity
Ig germline alpha-chain gene C-switch region IgA 2.2 I 0.7 NC inflammation/immunity
germline heavy-chain gene V region IgH 2.3 I 0.6 NC inflammation/immunity
killer cell lectin-like receptor subfamily G, member 1 Klrg1 2.3 I  0.1 NC inflammation/immunity
Eosinophil granule major basic protein precursor (MBP)
(proteoglycan 2)
Mbp 2.3 I  0.7 NC inflammation/immunity
regulatory factor X-associated ankyrin-containing protein Rfxank 3.5 I  1 NC inflammation/immunity
surfactant associated protein D Sftpd 3.4 I 1.2 NC inflammation/immunity
secretory leukocyte protease inhibitor Slpi 2.4 I 0.7 NC inflammation/immunity
kidney expressed gene 1 Keg1 2.2 MI  0.3 NC other/unknown
olfactory receptor 37c Olfr37c 2.1 I 1 NC other/unknown
submaxillary gland androgen regulated protein 2
(MSG2, Vcs2)
Smr2 2.7 I  1.1 NC other/unknown
adenylate cyclase activating polypeptide 1 Adcyap1 2.6 I 1.7 NC signaling
embryonic stem cell phosphatase Esp 2.9 I 1.2 NC signaling
growth factor receptor bound protein 7 Grb7 2.5 I 0.9 NC signaling
MAD homolog 3 (Drosophila) Madh3 2.6 I 0.6 NC signaling
protein tyrosine phosphatase, receptor type, D Ptprd 2.4 I  1.1 NC signaling
regulator of G-protein signaling 9 Rgs9 2.8 I  1 NC signaling
ubiquitin conjugating enzyme 7 interacting protein 3 Ubce7ip3 2.7 I  0.9 NC signaling
distal-less homeobox 4 Dlx4 3.3 I  2.7 D transcription factor
homeobox A11 Hoxa11 2.6 I 0.7 NC transcription factor
heat shock factor 2 Hsf2 2.7 I  0.7 NC transcription factor
myeloblastosis oncogene-like 1 Mybl1 2.5 I 0.9 NC transcription factor
paired box gene 3 Pax3 3 I 0.8 NC transcription factor
annexin A7 Anxa7 2.4 I 0.6 NC transport/sorting
bassoon Bsn 3.7 I  1.5 D transport/sorting
chaperonin subunit 6a (zeta) Cct6a 2.4 I  1.8 MD transport/sorting
frequenin homolog (Drosophila) (NCS-1) Freq 4 I  0.2 NC transport/sorting
solute carrier family 15 (H+/peptide transporter), member 2 Slc15a2 3.5 I 0.5 NC transport/sorting
solute carrier family 2 (facilitated glucose transporter), member 2 Slc2a2 3.3 I  0.2 NC transport/sorting
leukemia-associated gene Lag 2.3 I 1 NC tumor-associated
regenerating islet-derived 2 Reg2 2.3 MI 0.4 NC tumor-associated
budding uninhibited by benzimidazoles 3 homolog
(Saccharomyces cerevisiae)
Bub3 1.7 MI  2.2 D cell cycle/apoptosis
fibrillin 1 Fbn1 1.2 NC  2.6 D cell–cell interactions
junction cell adhesion molecule 3 Jcam3 1 NC  2.1 D cell–cell interactions
syndecan 1 Sdc1 1 NC  2 MD cell–cell interactions
myosin IF Myo1f 2.1 I  2.5 D cytoskeleton
sarcoglycan, beta (43 kDa dystrophin-associated glycoprotein) Sgcb  0.6 NC  2.6 D cytoskeleton
stathmin 1 Stmn1 0.1 NC  2.3 D cytoskeleton
(continued on next page)
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Gene Name WT + Ig Tg6 + Ig Function
Changea Callb Change Call
titin-cap Tcap 1.7 MI  2.2 D cytoskeleton
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 50 Ddx50 0.1 NC  2.3 D DNA/RNA metabolism
mitogen- and stress-activated protein kinase-2 (mMSK2) Rps6ka4 0.6 NC  2.3 D DNA/RNA metabolism
sudD, suppressor of bimD6 homolog (Aspergillus nidulans) Sudd 0.3 NC  2.5 D DNA/RNA metabolism
cytochrome P450, 4a10 Cyp4a10 1 NC  2 D enzymes/metabolism
glutamic acid decarboxylase 1 Gad1  1.2 NC  2.6 D enzymes/metabolism
methionyl aminopeptidase 1 Metap1 1.6 NC  2.9 D enzymes/metabolism
sulfatase 2 Sulf2  1.4 NC  2.2 MD enzymes/metabolism
histocompatibility 2, T region locus 24 H2-T24  0.4 NC  2.1 MD inflammation/immunity
extrachromosomal DNA for V kappa and J kappa coding joint Ig  1.1 NC  2.8 D inflammation/immunity
interleukin 4 Il4  0.2 NC  2.9 D inflammation/immunity
single chain antibody scFv (scFvP25) ScFvP2  1.7 NC  2.3 D inflammation/immunity
tumor necrosis factor receptor superfamily, member 18 Tnfrsf18 1.8 I  3.3 D inflammation/immunity
Homeobox D8 D8 1.6 NC  2.3 D transcription factor
ATPase, Cu2 + transporting, alpha polypeptide Atp7a 0.4 NC  2.6 D transport/sorting
heat shock protein 8 Hspa8 0.8 NC  2.4 D transport/sorting
transient receptor potential cation channel, subfamily M, member 7 Trpm7 0.8 NC  2.2 MD transport/sorting
Identical microarray experiments were performed in duplicate with unstimulated and BCR-activated (+Ig) B cells from wild-type (WT) and LMP2A Tg6
transgenic mice.
a Average fold change in gene expression, calculated from Signal Log Ratios, following BCR activation. All values had a probability of <0.05 in a t-
distribution. Negative values indicate decreased expression.
b Change call assigned by the Affymetrix GeneChip software: Increase (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), Decrease (D).
Table 1 (continued)
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levels were induced similarly upon BCR activation in both
wild-type and LMP2A Tg6 B cells. In contrast to human B
cell lines, which demonstrate constitutive tyrosine phosphor-
ylation in the presence of LMP2A, B cells from LMP2ATg6
transgenic mice do not exhibit constitutive phosphotyrosine
activity. This is most likely due to lower basal levels of
LMP2A expression in primary murine Tg6 B cells.
Overall analysis of gene expression following BCR
activation
Total RNA was isolated from unstimulated and BCR-
activated B cells from wild-type and LMP2ATg6 transgenic
mice and utilized for microarray analyses. Gene expression
was analyzed after 5 h of BCR activation to detect both early
and late mRNA induction as well as mRNA down-regulation
or degradation that may result from BCR signaling. RNA
expression levels for genes contained in Affymetrix micro-
arrays were measured by hybridization intensity and the
relative abundance of each gene was expressed as the
‘‘average difference’’. This value represents the difference
in fluorescence intensity for RNAs hybridized to matched
versus mismatched oligos. A complete listing of the micro-
array results is available at http://bugs.mimnet.northwestern.
edu/mimweb/microarray.htm. The average differences in
hybridization intensities for genes in each sample were
plotted in graphs to demonstrate the overall similarities and
differences in gene expression (Fig. 2). Fig. 2A demonstrates
a representative comparison of gene expression in B cells
from wild-type (WT) mice, unstimulated (unst) versus BCR-
activated (+Ig). Many differences in gene expression (two-fold or higher) were induced upon BCR stimulation and are
indicated as outliers closer to the two axes in the scatter plot
(Fig. 2A). Of over 10,000 unique transcripts identified by the
microarrays, 158 genes were induced and 127 genes were
down-regulated following BCR activation. In contrast, BCR
activation of B cells from LMP2A Tg6 transgenic mice did
not appear to induce significant changes in gene transcription
when compared to expression in unstimulated cells (Fig.
2B). In BCR-activated B cells from LMP2A Tg6 mice,
expression of 41 genes was induced and 73 genes were
down-regulated. A comparison of gene expression following
BCR activation in B cells from wild-type versus LMP2ATg6
transgenic mice revealed many significant differences in
gene transcription when compared to untreated B cells from
the same mice (compare Figs. 2C and 2D). In fact, the scatter
plot showing gene expression in unstimulated B cells from
wild-type versus LMP2A Tg6 mice (Fig. 2D) indicates that
these two groups are transcriptionally similar before BCR
activation. These results suggest that LMP2A alters the
normal regulation of gene transcription that occurs following
BCR activation.
Differential changes in gene expression following BCR
activation
The changes in gene expression induced upon BCR
activation were compared between B cells from wild-type
and LMP2A Tg6 transgenic mice. Of the genes that were
altered upon BCR activation, expression of 61 genes was
statistically different in BCR-activated B cells fromwild-type
versus LMP2A Tg6 transgenic mice. Of the 61 genes, 49
(80%) were up-regulated and 12 (20%) were down-regulated
T. Portis, R. Longnecker / Virolupon BCR stimulation when compared to B cells from
LMP2A Tg6 mice (Fig. 3A). Expression of 45 genes was
statistically different in BCR-activated B cells from LMP2A
Tg6 transgenic mice versus wild-type mice. Of these, 20
(44%) were up-regulated and 25 (56%) were down-regulated
upon BCR stimulation when compared to B cells from wild-
type mice (Fig. 3A). The large difference in the percentage of
genes increased in B cells from wild-type versus LMP2ATg6
mice following BCR activation, together with differences
indicated in the scatter plots (Fig. 2), further suggests that
LMP2A represses the transcription of many genes that should
normally be induced upon BCR activation.
Differentially expressed genes in BCR-stimulated B cells
from non-transgenic and LMP2A Tg6 transgenic mice were
placed into categories based on protein function. Those genes
with unknown function or whose category placement was
unclear were designated as other/unknown. Fig. 3B indicates
the relative percentage of genes in each category whose
expression was differentially increased (bars 1 and 2) or
decreased (bars 3 and 4) upon BCR activation of B cells
from wild-type (bars 1 and 3) versus LMP2ATg6 transgenic
mice (bars 2 and 4).
Several categories of genes appeared to be specifically
altered by LMP2A following BCR activation. In general,
many genes involved in protein transport and sorting and
those involved in cell–cell interactions were increased in
BCR-activated B cells from wild-type mice, but decreased in
B cells from LMP2ATg6 transgenic mice (Fig. 3B, compare
bars 1 and 4). Similarly, a larger percentage of genes involved
in inflammation and immunity were increased in BCR-
activated B cells from wild-type mice compared to those
from LMP2ATg6 mice (Fig. 3B, compare bars 1 and 2). In
contrast, a larger percentage of genes encoding transcription
factors, involved in DNA/RNA metabolism, and associated
with cell cycle/apoptosis were increased in BCR-activated B
cells from LMP2A Tg6 transgenic mice when compared to
wild-type mice (Fig. 3B, compare bars 1 and 2).
Expression of genes encoding signaling proteins,
enzymes and those involved in protein metabolism, and
those associated with cell cycle/apoptosis was decreased
more significantly in B cells from wild-type versus
LMP2A Tg6 transgenic mice (Fig. 3B, compare bars 3
and 4). Expression of genes encoding cytoskeletal proteins
was only affected in BCR-activated B cells from LMP2A
Tg6 transgenic mice, both positively and negatively (Fig.
3B, bars 2 and 4). Taken together, these results suggest
that LMP2A prevents the induction of genes involved in
protein transport and sorting, cell–cell interactions, and
inflammation and immunity following BCR activation.
Furthermore, LMP2A prevents the down-regulation of
genes encoding signaling proteins, those involved in cell
cycle/apoptosis, and those encoding enzymes and involved
in protein metabolism following BCR activation. LMP2A
may be able to accomplish this by altering the expression
of genes encoding transcription factors and regulators of
DNA/RNA metabolism.Genes differentially expressed upon BCR activation
Table 1 lists the specific genes whose expression was
increased upon BCR activation of B cells from wild-type
mice, but not LMP2A Tg6 transgenic mice (first 49 genes),
or decreased in B cells from LMP2A Tg6 mice, but not
wild-type mice (last 25 genes). Shown is the average fold
change in gene expression from two separate, identical
experiments. Those genes with an average difference in
expression of twofold or greater, probability values of less
than 0.05, and Affymetrix calls other than no change (NC),
were considered significant. The Affymetrix call, based
upon statistical significance within probes sets, is listed,
along with the functional categories in which the genes were
placed for Fig. 3. As indicated previously and shown in
Table 1, expression of 49 genes was increased in BCR-
activated B cells from wild-type mice; however, no change
was detected in their expression in BCR-activated B cells
from LMP2A Tg6 transgenic mice. Genes that were only
induced upon BCR activation of B cells from wild-type
mice and possibly important for B-cell function included
genes involved in cell–cell interactions (Adam2, Lamb2,
Ncam2, Ndph, Nrp, S100a1), inflammation and immunity
(Cd160, IgA, IgH, Klrg1, Mbp, Rfxank, Sftpd, Slpi), and
protein transport and sorting (Anxa7, Bsn, Cct6a, Freq,
Slc15, Slc2). BCR activation of B cells from wild-type mice
also resulted in increased expression of various signaling
molecules that were not induced in B cells from LMP2A
Tg6 mice, including Adcyap1, Esp, Grb7, Madh3, Ptprd,
Rgs9, and Ubce7ip3. In contrast, activation of B cells from
LMP2ATg6 mice led to reduced expression of an important
cell cycle checkpoint gene, Bub3, as well as genes encoding
proteins involved in cell–cell interactions (Fbn1, Jcam3,
Sdc1), inflammation and immunity (MHC class II, Ig, Il-4,
ScFv, Tnfrsf18), and protein transport and sorting (Atp7a,
Hspa8, Trpm7). Expression of these genes was either
unchanged or increased in BCR-activated B cells from
non-transgenic mice (Table 1).
Table 2 lists the specific genes whose expression was
decreased upon BCR activation of B cells from wild-type,
but not LMP2A Tg6 transgenic mice (first 12 genes) or
increased in B cells from LMP2A Tg6 mice, but not wild-
type mice (last 20 genes). BCR activation of B cells from
wild-type mice resulted in decreased expression genes
encoding proteins involved in cell cycle/apoptosis (Pdcd2,
Rnf7), enzymes and those involved in protein metabolism
(Cmas, Dhcr7, Hsd17b4, Ptdss2), and inflammation and
immunity (Klrb1a, Tgfbr1, Vpreb3). Interestingly, BCR
activation of B cells from LMP2A Tg6 mice resulted in
increased expression of genes encoding proteins involved
in cell cycle/apoptosis (Cdkn2b, Rck1), DNA/RNA metab-
olism (Rpl19, Zfp179, Zfp312), and various transcription
factors (Nfib, Nr5a2, Sh2d2a, Smaf1, Sox18). Again,
expression of these genes was either unchanged or de-
creased in BCR-activated B cells from non-transgenic mice
(Table 2).
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Genes down-regulated in BCR-activated B cells from wild-type mice or induced in BCR-activated LMP2A Tg6 mice
Gene Name WT + Ig Tg6 + Ig Function
Changea Callb Change Call
programmed cell death 2 (RP-8) Pdcd2  2.3 D  0.6 NC cell cycle/apoptosis
ring finger protein 7 Rnf7  2.4 D  0.9 NC cell cycle/apoptosis
leucine rich repeat (in FLII) interacting protein 2 Lrrfip2  3.1 D 2 MI DNA/RNA metabolism
cytidine monophospho-N-acetylneuraminic acid synthetase Cmas  2.3 MD  0.8 NC enzymes/metabolism
7-dehydrocholesterol reductase Dhcr7  2.3 MD 0.8 NC enzymes/metabolism
hydroxysteroid (17-beta) dehydrogenase 4 Hsd17b4  2.4 D 1 NC enzymes/metabolism
phosphatidylserine synthase 2 Ptdss2  4.1 D  0.7 NC enzymes/metabolism
killer cell lectin-like receptor subfamily B member 1A (Ly55) Klrb1a  2.3 MD  1.1 NC inflammation/immunity
transforming growth factor, beta receptor I Tgfbr1  2.4 D  0.7 NC inflammation/immunity
pre-B lymphocyte gene 3 Vpreb3  4.5 D  1.7 MD inflammation/immunity
5-azacytidine induced gene 2 Azi2  2.1 D  1 NC other/unknown
protein phosphatase 1, regulatory (inhibitor) subunit 2 Ppp1r2  3.1 D 0.7 NC signaling
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) Cdkn2b  0.2 NC 2.8 I cell cycle/apoptosis
protein regulator of cytokinesis 1-like Rck1  0.3 NC 2.5 I cell cycle/apoptosis
myosin light chain, alkali, nonmuscle Myln  1.7 MD 2.2 I cytoskeleton
ribosomal protein L19 Rpl19 1.2 NC 3.2 I DNA/RNA metabolism
zinc finger protein 179 Zfp179  0.2 NC 3 I DNA/RNA metabolism
zinc finger protein 312 Zfp312  0.9 NC 3.1 I DNA/RNA metabolism
fatty acid binding protein 5, epidermal Fabp5  0.1 NC 3.9 I enzymes/metabolism
glutathione S-transferase, mu 3 Gstm3  0.5 NC 2 I enzymes/metabolism
pyruvate dehydrogenase E1 alpha 2 Pdha2 1 NC 2.4 I enzymes/metabolism
prostaglandin-endoperoxide synthase 1 Ptgs1 0.7 NC 2.2 MI enzymes/metabolism
lymphocyte antigen 6 complex, locus E Ly6e 0.5 NC 3 I inflammation/immunity
carnitine deficiency-associated gene expressed in ventricle 3 Cdv3  1.5 NC 2.7 I other/unknown
guanine nucleotide binding protein (G protein), gamma 4 subunit Gng4 1.7 NC 2.1 MI signaling
pleckstrin homology, Sec7 and coiled/coil domains 3 Pscd3  0.6 NC 2.5 I signaling
nuclear factor I/B Nfib  0.2 NC 2.6 I transcription factor
nuclear receptor subfamily 5, group A, member 2 (LRH-1) Nr5a2 1.2 NC 2.1 I transcription factor
SH2 domain protein 2A Sh2d2a  0.2 NC 2.3 I transcription factor
Smaf1 SMAF1 0.8 NC 2.4 I transcription factor
SRY-box containing gene 18 Sox18 0 NC 2.2 MI transcription factor
rab3A gene Rab3A  6.2 D 5.1 I transport/sorting
Identical microarray experiments were performed in duplicate with unstimulated and BCR-activated (+Ig) B cells from wild-type (WT) and LMP2A Tg6
transgenic mice.
a Average fold change in gene expression, calculated from Signal Log Ratios, following BCR activation. All values had a probability of <0.05 in a t-
distribution. Negative values indicate decreased expression.
b Change call assigned by the Affymetrix GeneChip software: Increase (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), Decrease (D).
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the transcriptional induction of many genes following BCR
activation, while inhibiting the down-regulation of other
genes involved in normal B-cell activation. Furthermore,
LMP2A induces the expression of various transcription
factors and genes associated with DNA/RNA metabolism,
which may allow for the altered transcriptional regulation
observed in BCR-activated B cells from LMP2A Tg6 mice.Discussion
The identification of altered transcriptional regulation
following BCR activation of B cells from LMP2A Tg6
mice is similar to our recent observation that LMP2A
globally represses gene transcription necessary for proper
B-cell development when expressed during B lymphopoi-
esis in the LMP2A TgE transgenic line (Portis and Long-necker, 2003). In these mice, signaling through the pre-BCR
appears to be inhibited or bypassed by LMP2A as indicated
by the presence of improperly developed, BCR-negative B
cells in peripheral lymphoid organs. The use of LMP2ATg6
mice, in which B cells express a BCR despite LMP2A
expression, provides an alternative model in which to more
specifically study the effects of LMP2A on BCR signaling
in vivo.
It has been clearly demonstrated using human cell lines
in vitro that LMP2A interferes with signaling through the
BCR. IgM crosslinking of B cells expressing LMP2A fails
to activate calcium mobilization and phosphorylation of
downstream BCR signaling components (Miller et al.,
1993, 1995). The inhibition of BCR signaling by LMP2A
correlates with lower levels of EBV lytic replication, which
has implicated LMP2A as a critical mediator of viral latency
(Miller et al., 1994). One mechanism by which LMP2A
interferes with BCR signaling is thought to be through its
T. Portis, R. Longnecker / Virology 318 (2004) 524–533 531constitutive association with the tyrosine kinases Lyn and
Syk (Burkhardt et al., 1992), thereby inhibiting their re-
cruitment to the BCR upon activation.
In this report, we observed equivalent levels of tyrosine
phosphorylation in B cells from non-transgenic and LMP2A
Tg6 transgenic mice following BCR activation. In primary
murine splenic B cells, LMP2A is expressed at much lower
levels than in established, EBV-transformed human lympho-
blastoid cell lines (LCLs), which may explain the differences
observed in phosphotyrosine induction (Caldwell et al.,
2000). One might predict that the repression in gene tran-
scription that was observed following BCR activation of B
cells from LMP2ATg6 mice is consistent with the potential
transcriptional effects of BCR activation in the presence of a
constitutive, basal signal provided by LMP2A in human cell
lines in vitro. Furthermore, apparently normal induction of
tyrosine phosphorylation in the presence of transcriptional
alterations suggests that LMP2A does not block BCR sig-
naling, rather somehow alters normal signal transduction
pathways in order to repress downstream gene transcription.
Altered BCR signaling might then allow for the survival of
latently infected B cells in the absence of classical BCR
activation, which would induce lytic replication.
It remains to be determined exactly how altered BCR
signaling and transcriptional regulation by LMP2A affects
normal B-cell function. Because we chose to simplify the
transcriptional analysis by measuring gene expression at one
time-point, 5 h after BCR activation, it is possible that we
were unable to detect additional changes in short-lived,
early gene induction following Ig treatment. Additionally,
we cannot rule out the possibility that LMP2A mediates a
delay in normal transcriptional induction or down-regulation
following BCR activation, which might be observed at a
later time point. However, our results indicate that LMP2A
alters normal gene transcription in some manner, whether by
complete repression or delayed expression, which may
contribute to the maintenance of EBV latency. It is interest-
ing to note that many genes that were not induced following
BCR stimulation in LMP2A Tg6 B cells when compared to
wild-type B cells included those involved in protein trans-
port and sorting, cell–cell interactions, and inflammation
and immunity. This may highlight an important role for
LMP2A in regulating or modulating specific B-cell func-
tions, thereby allowing EBV to persist during latency. In
addition, genes that were induced in LMP2A Tg6 B cells
when compared to wild-type B cells included genes encod-
ing transcription factors, involved in DNA/RNA metabo-
lism, and associated with cell cycle/apoptosis. These
observations may also indicate an essential role for LMP2A
in vivo, insuring that latently infected cells are resistant to
apoptosis or other stimuli that may detrimentally affect the
survival of EBV-infected cells in the human host.
In summary, we have compared gene expression in B
cells from wild-type versus LMP2A Tg6 transgenic mice
following BCR activation. We demonstrated that, before
BCR activation, the transcriptional profile of B cells fromLMP2A Tg6 mice was similar to that of wild-type mice.
However, upon BCR activation, LMP2A appeared to re-
press both the induction and down-regulation of many genes
that share common functions and are likely to be important
for normal B-cell activation. Furthermore, BCR activation
of B cells from LMP2A Tg6 transgenic mice resulted in
increased expression of genes encoding transcription factors
and regulators of DNA/RNA metabolism, which may be
responsible for alterations in gene transcription following
BCR activation. Future studies utilizing this mouse model to
address the exact mechanisms by which LMP2A alters
signaling and gene expression following BCR activation
may provide better insight into the ways in which LMP2A
promotes latency in EBV-infected B lymphocytes.Materials and methods
Isolation of primary B cells from mice
Construction and characterization of the EA Tg6
LMP2A transgenic mice have been described previously
(Caldwell et al., 2000). All animals were housed at the
Northwestern University Center for Experimental Animal
Resources in accordance with university animal welfare
guidelines. To isolate primary B cells, spleens were
dissociated between frosted slides in RPMI to prepare
single cell suspensions. Red blood cells were lysed and B
cells were negatively selected on magnetic cell sorting
(MACS) columns utilizing magnetic beads coated with
CD43 antibodies (Miltenyi Biotec, Auburn, CA). B cells
were tested for purity by FACS analysis and cells shown
to be >95% CD19+ B cells by flow cytometry were
utilized for microarray analyses. B cells were placed at
10  106 cells/ml in 2 ml of RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS), 1000
U/ml penicillin, and 1000 Ag/ml streptomycin. Cells were
either left untreated or treated with 25 Ag goat anti-mouse
Ig (H + L) (Southern Biotechnology, Birmingham, AL)
for a total of 5 h at which time RNA was isolated. After
5 min of antibody treatment, 5  106 cells were removed
for isolation of protein for Western blots.
Protein isolation and Western blots
B cells (5  106) were lysed in buffer containing 125
mM HEPES, pH 7.5, 750 mM NaCl, 50 mM MgCl2, 5
mM EDTA, 10% glycerol, 10 Ag/ml aprotinin, 10 Ag/ml
leupeptin, 25 mM NaF, and 1 mM sodium orthovanadate.
Protein levels were measured by Bradford assay (Bio-
Rad, Hercules, CA) and equivalent amounts of protein
were subjected to heat denaturation at 70 jC for 10 min.
Samples were run on 4–15% SDS-PAGE gels (Bio-Rad)
at 100 V for 1.5 h and transferred to Immobilon-P
membranes (Millipore, Bedford, MA). Recombinant anti-
phosphotyrosine, RC20, conjugated to horseradish per-
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diluted 1:2000 in TBST (150 mM NaCl, 50 mM Tris–
Cl, pH 8, and 0.05% Tween 20) supplemented with 5%
BSA and utilized to detect tyrosine phosphorylation,
followed by ECL detection (Amersham Pharmacia Bio-
tech, Piscataway, NJ) and autoradiography.
RNA preparation and microarray experiments
Total RNA was extracted from B cells according to the
Trizol reagent protocol (Invitrogen, Carlsbad, CA). RNA
was then subjected to cleanup using the Qiagen Rneasy
Mini Kit according to the RNA cleanup protocol (Qiagen,
Valencia, CA). Aliquots of RNAwere then removed and run
on 1% agarose/formaldehyde gels to verify that no degra-
dation occurred. Additionally, OD readings were taken and
20 Ag of total RNA having OD A260/A280 readings between
1.9 and 2.1 was utilized for reverse transcription. Double-
stranded cDNA was then generated according to the Super-
script Double-Stranded cDNA Synthesis Kit (Invitrogen)
using an oligo dT/T7 primer (5V-GGCCAGTGAATTGTAA-
TACGACTCACTATAGGGAGGCGG-(dT)24-3V). Follow-
ing phenol/chloroform extraction and ethanol precipitation,
cRNAwas in vitro transcribed and labeled with biotin using
the Enzo Bioarray RNA Transcription Labeling Kit (Affy-
metrix, Santa Clara, CA). The cRNA was purified using
CHROMA SPIN 100 columns (Clontech, Palo Alto, CA)
and ethanol precipitated. cRNA having OD A260/A280 read-
ings between 1.9 and 2.1 were again run on agarose/
formaldehyde gels to check for transcripts ranging between
35 and 200 bases and 20 Ag of these products was
fragmented in fragmentation buffer containing 200 mM
Tris-acetate, pH 8.1, 500 mM KOAc, and 150 mM MgOAc,
at 95 jC for 35 min. Fragmented, biotinylated cRNA was
then submitted for hybridization by the Children’s Memorial
Institute for Education and Research (CMIER) microarray
facility at Northwestern University. The murine genome
U74A chips were purchased from Affymetrix and utilized
for analysis.
Statistical significance of differential expression
The Affymetrix system of expression quantification using
perfect and mismatched oligonucleotides was used in con-
junction with the system of background detection. At least
two separate, identical experiments comparing gene tran-
scription in untreated and BCR-activated B cells from
LMP2A transgenic mice and non-transgenic littermates were
performed. The entire data set for these experiments is
available at http://bugs.mimnet.northwestern.edu/mimweb/
microarray.htm. The GeneSpring data analysis program
(Silicon Genetics, Redwood City, CA) was utilized to
generate scatter plots for overall expression comparisons.
A t-distribution was applied to the differences in gene
expression between BCR activation in B cells from wild-
type versus LMP2A Tg6 transgenic mice. Genes withchanges in differential expression values of twofold or
greater, probability values less than 0.05, and Affymetrix
calls other than no change were considered statistically
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